High-density lipoprotein profiling changes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: A cohort study

Journal of Rheumatology

Volumn 40, Issue 6, 2013, Pages 825-830

  Jamnitski, Anna ^a   Levels, Johannes H ^b   Van Den Oever, Inge A ^a   Nurmohamed, Michael T ^a,c  

^a Reade   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular risk; High density; Lipid profile; Lipoproteins; Rheumatoid arthritis; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PREDNISOLONE; SERUM AMYLOID A; SERUM AMYLOID A 1; SERUM AMYLOID A 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; ENZYME ACTIVITY; EUROPEAN LEAGUE AGAINST RHEUMATISM; FEMALE; HEALTH CARE ORGANIZATION; HUMAN; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME;

CARDIOVASCULAR RISK; HIGH-DENSITY LIPOPROTEINS; LIPID PROFILE; RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR INHIBITORS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS, HDL; MALE; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878644886     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121358     Document Type: Article

References (10)

1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
2. Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology 2011;50:518-31.
3. Van Sijl AM, Peters MJ, Knol DL, de Vet RH, Sattar N, Dijkmans BA, et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: A meta-analysis. Semin Arthritis Rheum 2011;41:393-400.
4. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
5. van Eijk IC, de Vries MK, Levels JH, Peters MJ, Huizer EE, Dijkmans BA, et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009;60:1324-30.
6. Levels JH, Bleijlevens B, Rezaee F, Aerts JM, Meijers JC. SELDI-TOF mass spectrometry of high-density lipoprotein. Proteome Sci 2007;5:15.
7. Levels JH, Geurts P, Karlsson H, Maree R, Ljunggren S, Fornander L, et al. High-density lipoprotein proteome dynamics in human endotoxemia. Proteome Sci 2011;9:34.
8. Watanabe J, Charles-Schoeman C, Milao Y, Elashoff D, Lee YY, Katselis G, et al. Proteomic profiling following immunoaffinity capture of HDL: Association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis. Arthritis Rheum 2012;64:1828-37.
9. Heinecke JW. The HDL proteome: A marker - and perhaps mediator - of coronary artery disease. J Lipid Res 2009;50 Suppl:S167-71.
10. Rohrer L, Hersberger M, von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004;15:269-78.